Gene · 4919
Papers2,258
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 2,258
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Polyoxygenated cembrane-type diterpenes from the Hainan soft coral Lobophytum crassum as a promising source of anticancer agents with ErbB3 and ROR1 inhibitory potential. | Acta Pharmacol Sin | 2025 | 39075227 | PubTator, text mining | PubMed |
| Receptor tyrosine kinase-like orphan receptor serves as a potential target in cancer immunotherapy. | J Leukoc Biol | 2025 | 38973261 | PubTator, text mining | PubMed |
| Associations between plasma metabolism-associated proteins and future development of giant cell arteritis: results from a prospective study. | Rheumatology (Oxford) | 2025 | 38310345 | PubTator, text mining | PubMed |
| Isolating Small Extracellular Vesicles from Small Volumes of Blood Plasma using size exclusion chromatography and density gradient ultracentrifugation: A Comparative Study. | bioRxiv | 2025 | 37961562 | PubTator, text mining | PubMed |
| Genome-wide association neural networks identify genes linked to family history of Alzheimer's disease. | Brief Bioinform | 2024 | 39775791 | PubTator, text mining | PubMed |
| Insights into genetic aberrations and signalling pathway interactions in chronic lymphocytic leukemia: from pathogenesis to treatment strategies. | Biomark Res | 2024 | 39732734 | PubTator, text mining | PubMed |
| Twofold Expression of Receptor Tyrosine Kinase 2 (ROR2) in Giant Cell Tumors of Bone: Outcome of a Case‒Control Study. | Indian J Surg Oncol | 2024 | 39555360 | PubTator, text mining | PubMed |
| Therapeutic advances in the targeting of ROR1 in hematological cancers. | Cell Death Discov | 2024 | 39551787 | PubTator, text mining | PubMed |
| Highly specific detection of ROR1 cancer biomarker with bipolar electrochemiluminescence. | Mikrochim Acta | 2024 | 39514011 | PubTator, text mining | PubMed |
| Determining the effect of long non-coding RNA maternally expressed gene 3 (lncRNA MEG3) on the transcriptome profile in cervical cancer cell lines. | Genomics | 2024 | 39510199 | PubTator, text mining | PubMed |
| Tumour assessment of ROR1 levels in various adult leukaemia and lymphoma types. | PLoS One | 2024 | 39495778 | PubTator, text mining | PubMed |
| A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population. | Clin Pharmacokinet | 2024 | 39438409 | PubTator, text mining | PubMed |
| [Corrigendum] miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer. | Int J Oncol | 2024 | 39329219 | PubTator, text mining | PubMed |
| Profiling of B cells and their subsets by whole blood gene expression analysis versus flow cytometry in multiple sclerosis. | Mult Scler Relat Disord | 2024 | 39317145 | PubTator, text mining | PubMed |
| Engineering potent chimeric antigen receptor T cells by programming signaling during T-cell activation. | Sci Rep | 2024 | 39266656 | PubTator, text mining | PubMed |
| Unveiling the state of the art: a systematic review and meta-analysis of paper-based microfluidic devices. | Front Bioeng Biotechnol | 2024 | 39234268 | PubTator, text mining | PubMed |
| The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management. | Adv Pharm Bull | 2024 | 39206402 | PubTator, text mining | PubMed |
| BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia. | Expert Rev Hematol | 2024 | 39163531 | PubTator, text mining | PubMed |
| Unlocking the potential: advancements and future horizons in ROR1-targeted cancer therapies. | Sci China Life Sci | 2024 | 39145866 | PubTator, text mining | PubMed |
| [Screening and validation of therapeutic targets for chronic sinusitis with nasal polyps based on proteomics]. | Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi | 2024 | 39107122 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4919/papers?page=8